Background : Renal disease is associated with ineffective erythropoiesis. In such patient populations, reports on the extent, complications, and management of iatrogenic iron overload (IO), following repeated blood transfusions and intravenous iron supplementation, are rare. Patients and Methods : Over the past 5 years, 3572 patients on different modalities of renal therapies, viz. conservative, maintenance hemodialysis, maintenance peritoneal dialysis, and kidney transplantation, were screened for IO and its subsequent liver, endocrine, and heart complications. Diagnosis of IO was established by high transferrin saturation %, serum ferritin, bone marrow stores, and CT density. Liver disease was suspected with abnormal liver tests and abdominopelvic sonography. After exclusion of other causes of liver diseases, a liver biopsy was done to assess for IO-hepatopathy. In those patients, basal and dynamic hormonal tests as well as echocardiography were used to assess for IO-endocrinopathy and IO-cardiopathy. Results : A total of 823 (23%) had IO, of whom 23 patients with severe and long-standing exposure had IO-hepatopathy (6 with severe hemosiderosis and 17 with cirrhosis). In those patients, 2 had pituitary disease and 2 had dilated cardiomyopathy. Weekly phlebotomy for 1 month followed by twice monthly phlebotomy normalized their iron balance by 3 months in all patients with IO and halted the liver, endocrine, and heart complications, in the affected ones, by 42 ± 11 months of follow-up. Conclusion : IO-hepatopathy, endocrinopathy, and cardiomyopathy can develop following inappropriate and excessive intravenous iron infusions in renal patients on different RRT. Vigilant monitoring of their hematinic therapy is indicated and therapeutic phlebotomy is useful in its management.
Tian, Y., Tian, Y., Yuan, Z., Zeng, Y., Wang, S., Fan, X., et al . (2022) Iron Metabolism in Aging and Age-Related Diseases. International Journal of Molecular Sciences , 23, Article 3612. https://doi.org/10.3390/ijms23073612
Madiwale, T. and Liebelt, E. (2006) Iron: Not a Benign Therapeutic Drug. Current Opinion in Pediatrics , 18, 174-179. https://doi.org/10.1097/01.mop.0000193275.62366.98
Powell, L.W., Nathan Subramaniam, V. and Yapp, T.R. (2000) Haemochromatosis in the New Millenium. Journal of Hepatology , 32, 48-62. https://doi.org/10.1016/s0168-8278(00)80415-8
Baddam, S. and Chen, R.J. (2025) Iron Overload and Toxicity. StatPearls.
Canavesi, E., Alfieri, C., Pelusi, S. and Valenti, L. (2012) Hepcidin and HFE Protein: Iron Metabolism as a Target for the Anemia of Chronic Kidney Disease. World Journal of Nephrology , 1, 166. https://doi.org/10.5527/wjn.v1.i6.166
Richardson, K.J., McNamee, A.P. and Simmonds, M.J. (2018) Haemochromatosis: Pathophysiology and the Red Blood Cell1. Clinical Hemorheology and Microcirculation , 69, 295-304. https://doi.org/10.3233/ch-189128
Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. and Adamson, J.W. (1987) Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin. Results of a Combined Phase I and II Clinical Trial. New England Journal of Medicine , 316, 73-78. https://doi.org/10.1056/nejm198701083160203
Kuji, T., Toya, Y., Fujikawa, T., Kakimoto-Shino, M., Nishihara, M., e t al . (2015) Acceleration of Iron Utilization after Intravenous Iron Administration during Activated Erythropoiesis in Hemodialysis Patients: A Randomized Study. Therapeutic Apheresis Dialysis , 19, 131-137. https://doi.org/10.1111/1744-9987.12237
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., et al . (2004) IL-6 Mediates Hypoferremia of Inflammation by Inducing the Synthesis of the Iron Regulatory Hormone Hepcidin. Journal of Clinical Investigation , 113, 1271-1276. https://doi.org/10.1172/jci200420945
Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., et al . (2004) Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science , 306, 2090-2093. https://doi.org/10.1126/science.1104742
Nashwan, A.J., Abuawwad, M.T., Jaradat, J.H., Ibraheem, A., Yassin, M.A. and Taha, M.J.J. (2024) Prevalence of Iron Overload in Patients with Chronic Kidney Disease on Peritoneal Dialysis: A Scoping Review. Health Science Reports , 7, e2255. https://doi.org/10.1002/hsr2.2255
Nashwan, A.J., Yassin, M.A., Abd‐Alrazaq, A., Shuweihdi, F., Othman, M., Abdul Rahim, H.F., et al . (2022) Hepatic and Cardiac Iron Overload Quantified by Magnetic Resonance Imaging in Patients on Hemodialysis: A Systematic Review and Meta‐Analysis. Hemodialysis International , 27, 3-11. https://doi.org/10.1111/hdi.13054
Holman, R., Olynyk, J.K., Kulkarni, H. and Ferrari, P. (2017) Characterization of Hepatic and Cardiac Iron Deposition during Standard Treatment of Anaemia in Haemodialysis. Nephrology , 22, 114-117. https://doi.org/10.1111/nep.12735
Roa, K.V. and Anderson, R. (1985) Hemosiderosis and Hemochromatosis in Renal Transplant Recipients. Clinical and Pathological Features, Diagnostic Correlation, Predisposing Factors and Treatment. American Journal of Nephrology , 5, 419-430.
Blunden, R.W., Lloyd, J.V., Rudzki, Z. and Kimber, R.J. (1981) Changes in Serum Ferritin Levels after Intravenous Iron. Annals of Clinical Biochemistry : International Journal of Laboratory Medicine , 18, 215-217. https://doi.org/10.1177/000456328101800405
Cecchin, E., De Marchi, S., Querin, F., Marin, M.G., Fiorentino, R. and Tesio, F. (1990) Efficacy of Hepatic Computed Tomography to Detect Iron Overload in Chronic Hemodialysis. Kidney International , 37, 943-950. https://doi.org/10.1038/ki.1990.69
Salomao, M.A. (2021) Pathology of Hepatic Iron Overload. Clinical Liver Disease , 17, 232-237. https://doi.org/10.1002/cld.1051
Pietrangelo, A. (2010) Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment. Gastroenterology , 139, 393-408.e2. https://doi.org/10.1053/j.gastro.2010.06.013
Suprapti, E., Hadju, V., Ibrahim, E., Indriasari, R., Erika, K.A. and Balqis, B. (2025) Anemia: Etiology, Pathophysiology, Impact, and Prevention: A Review. Iranian Journal of Public Health , 54, 509-520. https://doi.org/10.18502/ijph.v54i3.18244
Hashmi, M.F., Shaikh, H. and Rout, P. (2024) Anemia of Chronic Kidney Disease. StatPearls.
El-Reshaid, K., Johny, K.V., Hakim, A., Kamel, H., Sebeta, A., Hourani, H., et al . (2009) Erythropoietin Treatment in Haemodialysis Patients with Iron Overload. Acta Haematologica , 91, 130-135. https://doi.org/10.1159/000204318
Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., et al . (1998) The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin. New England Journal of Medicine , 339, 584-590. https://doi.org/10.1056/nejm199808273390903
Coyne, D.W., Kapoian, T., Suki, W., Singh, A.K., Moran, J.E., Dahl, N.V., et al . (2007) Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. Journal of the American Society of Nephrology , 18, 975-984. https://doi.org/10.1681/asn.2006091034
Palmer, S.C., Navaneethan, S.D., Craig, J.C., Johnson, D.W., Tonelli, M., Garg, A.X., et al . (2010) Meta-Analysis: Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease. Annals of Internal Medicine , 153, 23-33. https://doi.org/10.7326/0003-4819-153-1-201007060-00252
Kotla, N.K., Dutta, P., Parimi, S. and Das, N.K. (2022) The Role of Ferritin in Health and Disease: Recent Advances and Understandings. Metabolites , 12, Article 609. https://doi.org/10.3390/metabo12070609
Lowe, D., Sanvictores, T., Zubair, M. and John, S. (2026) Serum Alkaline Phosphatase: Clinical and Laboratory Perspectives. StatPearls.
Olynyk, J.K. and Ramm, G.A. (2022) Hemochromatosis. New England Journal of Medicine , 387, 2159-2170. https://doi.org/10.1056/nejmra2119758